On a study in which the conclusion states, in part, "Use of minimal  
aliquots of L-aspartic acid and EHC for ß-glucuronidase inhibition  
results in increased fecal bilirubin excretion and less jaundice,  
without disruption of the breastfeeding experience. Decreased  
jaundice in the W/C group, which lacked a ß-glucuronidase inhibitor,  
suggests a different mechanism."

On 10/08/2005, at 11:02, Arly wrote:

> My guess is that the researchers have already been approached by a
> pharmaceutical/infant formula company.

A google/patent search reveals that the principal author already  
holds a 2002 patent for the use of aspartic and/or malic acids in the  
prevention of neonatal jaundice.

http://www.warf.org/ipstatus/P99139US.PDF

Lara Hopkins
             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html